Evidence map›Paper›PMID 34000363›Full record

ReviewThe ocular surface2021

Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Rohan Bir Singh, Lingjia Liu, Ann Yung, Sonia Anchouche, Sharad K Mittal, Tomas Blanco, Thomas H Dohlman, Jia Yin, Reza Dana

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The ocular surface, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Rohan Bir SinghLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Lingjia LiuLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Ann YungLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Sonia AnchoucheLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA; Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Sharad K MittalLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Tomas BlancoLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Thomas H DohlmanLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Jia YinLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Reza DanaLaboratory of Corneal Immunology, Transplantation and Regeneration, Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. Electronic address: reza_dana@meei.harvard.edu.
Massachusetts Eye and Ear Infirmary · US

Funding

MECHANISMS OF SENSITIZATION IN HIGH-RISK CORNEAL GRAFTSR01EY012963 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI DANA, REZA · 2000 to 2025
$15.1M
Mass Eye and Ear-Vision Clinical Scientist Development ProgramK12EY016335 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Reza Dana · 2004 to 2026
$12.3M
Immunopathogenic Mechanisms of Dry Eye DiseaseR01EY020889 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Reza Dana · 2010 to 2026
$7.9M
The Fibrosis-Immunity Interface in Corneal TransplantationK08EY031759 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI DOHLMAN, THOMAS · 2020 to 2024
$1.2M
NEI NIH HHS K08 EY031759NEI NIH HHS K12 EY016335NEI NIH HHS R01 EY012963NEI NIH HHS R01 EY020889
6 · The paper itself

Abstract

Conjunctival hyperemia is one of the most common causes for visits to primary care physicians, optometrists, ophthalmologists, and emergency rooms. Despite its high incidence, the treatment options for patients with conjunctival hyperemia are restricted to over-the-counter drugs that provide symptomatic relief due to short duration of action, tachyphylaxis and rebound redness. As our understanding of the immunopathological pathways causing conjunctival hyperemia expands, newer therapeutic targets are being discovered. These insights have also contributed to the development of animal models for mimicking the pathogenic changes in microvasculature causing hyperemia. Furthermore, this progress has catalyzed the development of novel therapeutics that provide efficacious, long-term relief from conjunctival hyperemia with minimal adverse effects.

Indexed as

ConjunctivitisHyperemiaAnimalsConjunctivaHumansOphthalmic SolutionsTime FactorsOphthalmic SolutionsConjunctival vasculatureConjunctivitisHyperemiaMicrocirculationOcular redness

Identifiers

PMID34000363
PMCPMC8328932
OpenAlexW3163857362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.